Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
By Y. Arabi, Y. Mandourah, F. Al-Hameed, A. Sindi, G. Almekhlafi, M. Hussein, J. Jose, Ruxandra Pinto, Awad Al-Omari, A. Kharaba and 19 more. American Journal of Respiratory and Critical Care Medicine, 2017
995 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/4a22beded7fbf2aaf23541e59d315f4a7bc4711a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance (2020, result): “Members of a WHO global network of clinicians and clinicians who have treated patients with SARS, MERS, or severe influenza have reviewed the recommendations (see Acknowledgements).”
- The Novel Coronavirus 2019 epidemic and kidneys (2020, background): “A subsequent retrospective, observational study of 309 patients with MERS showed that those who received high-dose steroids were more likely to require mechanical ventilation, vasopressors, and renal replacement therapy (RRT).(26) In a meta-analysis of corticosteroid use in patients with SARS, 4 stu”
- The SARS-CoV-2 outbreak: What we know (2020, background): “The general strategies include bed rest and supportive treatment, including antiviral therapy ([51]), antibioics application, immunomodulating therapy([52]), organ function support, respiratory support, bronchoalveolar lavage (BAL), blood purification and extracorporeal membrane oxygenation (ECMO)([”
- Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, positive): “Further, a study of patients given corticosteroids for MERS-CoV infection revealed delayed clearance of the virus and zero effect of corticosteroids on mortality [173] .”
- COVID-19 and diabetes: Knowledge in progress (2020, neutral): “[78] Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al.”
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial (2020, methodology): “26 The frequent use of corticosteroids in our patient group might have promoted viral replication, as observed in SARS 27 and MERS, 28 although these studies only reported pro longation of the detection of viral RNA, not infectious virus.”
- Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know (2020, background): “Corticosteroids for the treatment of coronavirusassociated pneumonia should be avoided unless other indications are present because they were not shown to be beneficial in MERS and could lead to delayed MERS-CoV clearance.(49) Therefore, decisions about the use of corticosteroids for fetal lung matu”
- Dexamethasone in Hospitalized Patients with Covid-19 (2021, neutral): “Black, Asian, or minority ethnic group 364 (17) 783 (18) 191 (12) 662 (17) 294 (29)”
- Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations (2020, neutral): “59 A systematic review of observational studies suggested that cortico steroids might increase mortality and secondary infections in influenza.”